Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 34

1.

Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial.

Baron JA, Sandler RS, Bresalier RS, Lanas A, Morton DG, Riddell R, Iverson ER, Demets DL.

Lancet. 2008 Nov 15;372(9651):1756-64. doi: 10.1016/S0140-6736(08)61490-7. Epub 2008 Oct 14. Erratum in: Lancet. 2008 Nov 15;372(9651):1732.

PMID:
18922570
[PubMed - indexed for MEDLINE]
2.

Rethinking statistical approaches to evaluating drug safety.

Liu JP.

Yonsei Med J. 2007 Dec 31;48(6):895-900.

PMID:
18159580
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer.

Kerr DJ, Dunn JA, Langman MJ, Smith JL, Midgley RS, Stanley A, Stokes JC, Julier P, Iveson C, Duvvuri R, McConkey CC; VICTOR Trial Group.

N Engl J Med. 2007 Jul 26;357(4):360-9.

PMID:
17652651
[PubMed - indexed for MEDLINE]
Free Article
4.

The VIOXX in Prostate Cancer Prevention study: cardiovascular events observed in the rofecoxib 25 mg and placebo treatment groups.

van Adelsberg J, Gann P, Ko AT, Damber JE, Logothetis C, Marberger M, Schmitz-Drager BJ, Tubaro A, Harms CJ, Roehrborn C.

Curr Med Res Opin. 2007 Sep;23(9):2063-70.

PMID:
17651539
[PubMed - indexed for MEDLINE]
5.

Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association.

Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA; American Heart Association.

Circulation. 2007 Mar 27;115(12):1634-42. Epub 2007 Feb 26. Review. No abstract available.

PMID:
17325246
[PubMed - indexed for MEDLINE]
Free Article
6.

Rofecoxib 12.5 mg, rofecoxib 25 mg, and celecoxib 200 mg in the treatment of symptomatic osteoarthritis: results of two similarly designed studies.

Smugar SS, Schnitzer TJ, Weaver AL, Rubin BR, Polis AB, Tershakovec AM.

Curr Med Res Opin. 2006 Jul;22(7):1353-67.

PMID:
16834834
[PubMed - indexed for MEDLINE]
7.

Treatment of patients with osteoarthritis with rofecoxib compared with nabumetone.

Weaver AL, Messner RP, Storms WW, Polis AB, Najarian DK, Petruschke RA, Geba GP, Tershakovec AM.

J Clin Rheumatol. 2006 Feb;12(1):17-25.

PMID:
16484875
[PubMed - indexed for MEDLINE]
8.

Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies.

Birbara C, Ruoff G, Sheldon E, Valenzuela C, Rodgers A, Petruschke RA, Chang DJ, Tershakovec AM.

Curr Med Res Opin. 2006 Jan;22(1):199-210.

PMID:
16393445
[PubMed - indexed for MEDLINE]
9.

Expression of concern: Bombardier et al., "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis," N Engl J Med 2000;343:1520-8.

Curfman GD, Morrissey S, Drazen JM.

N Engl J Med. 2005 Dec 29;353(26):2813-4. Epub 2005 Dec 8. No abstract available.

PMID:
16339408
[PubMed - indexed for MEDLINE]
Free Article
10.

Cyclooxygenase inhibition and cardiovascular risk.

Antman EM, DeMets D, Loscalzo J.

Circulation. 2005 Aug 2;112(5):759-70. Review. No abstract available.

PMID:
16061757
[PubMed - indexed for MEDLINE]
Free Article
11.

A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment.

Thal LJ, Ferris SH, Kirby L, Block GA, Lines CR, Yuen E, Assaid C, Nessly ML, Norman BA, Baranak CC, Reines SA; Rofecoxib Protocol 078 study group.

Neuropsychopharmacology. 2005 Jun;30(6):1204-15.

PMID:
15742005
[PubMed - indexed for MEDLINE]
Free Article
12.

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.

Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA; Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators.

N Engl J Med. 2005 Mar 17;352(11):1092-102. Epub 2005 Feb 15. Erratum in: N Engl J Med. 2006 Jul 13;355(2):221.

PMID:
15713943
[PubMed - indexed for MEDLINE]
Free Article
13.

Risk of cardiovascular events and rofecoxib: cumulative meta-analysis.

J√ľni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M.

Lancet. 2004 Dec 4-10;364(9450):2021-9.

PMID:
15582059
[PubMed - indexed for MEDLINE]
14.

Coxibs and cardiovascular disease.

Fitzgerald GA.

N Engl J Med. 2004 Oct 21;351(17):1709-11. Epub 2004 Oct 6. No abstract available.

PMID:
15470192
[PubMed - indexed for MEDLINE]
Free Article
15.

Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial.

Laine L, Maller ES, Yu C, Quan H, Simon T.

Gastroenterology. 2004 Aug;127(2):395-402.

PMID:
15300570
[PubMed - indexed for MEDLINE]
16.

Efficacy and safety of rofecoxib 12.5 mg versus nabumetone 1,000 mg in patients with osteoarthritis of the knee: a randomized controlled trial.

Kivitz AJ, Greenwald MW, Cohen SB, Polis AB, Najarian DK, Dixon ME, Moidel RA, Green JA, Baraf HS, Petruschke RA, Matsumoto AK, Geba GP; Protocol 085 Study Investigators.

J Am Geriatr Soc. 2004 May;52(5):666-74.

PMID:
15086644
[PubMed - indexed for MEDLINE]
17.

Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study.

Reines SA, Block GA, Morris JC, Liu G, Nessly ML, Lines CR, Norman BA, Baranak CC; Rofecoxib Protocol 091 Study Group.

Neurology. 2004 Jan 13;62(1):66-71.

PMID:
14718699
[PubMed - indexed for MEDLINE]
18.

Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.

Weir MR, Sperling RS, Reicin A, Gertz BJ.

Am Heart J. 2003 Oct;146(4):591-604. Review.

PMID:
14564311
[PubMed - indexed for MEDLINE]
19.

Efficacy and safety of rofecoxib in patients with chronic low back pain: results from two 4-week, randomized, placebo-controlled, parallel-group, double-blind trials.

Katz N, Ju WD, Krupa DA, Sperling RS, Bozalis Rodgers D, Gertz BJ, Gimbel J, Coleman S, Fisher C, Nabizadeh S, Borenstein D; Vioxx Chronic Low Back Pain Study Group.

Spine (Phila Pa 1976). 2003 May 1;28(9):851-8; discussion 859.

PMID:
12941996
[PubMed - indexed for MEDLINE]
20.

Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study.

Hawkey CJ, Laine L, Simon T, Quan H, Shingo S, Evans J; Rofecoxib Rheumatoid Arthritis Endoscopy Study Group.

Gut. 2003 Jun;52(6):820-6. Erratum in: Gut. 2003 Dec;52(12):1800.

PMID:
12740337
[PubMed - indexed for MEDLINE]
Free PMC Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk